60 Recruiting Acute Myeloid Leukemia Phase 2 Clinical Trials
Active phase 2 studies for acute myeloid leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Acute Myeloid Leukemia studiesPhase 2 Studies for Acute Myeloid Leukemia
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
📍 Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
View Study & Checklist ➔A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 Children's Hospital of Central California — Madera, California
View Study & Checklist ➔Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
View Study & Checklist ➔IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
📍 City of Hope National Medical Center /ID# 269273 — Duarte, California
View Study & Checklist ➔Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
📍 City of Hope — Duarte, California
View Study & Checklist ➔BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
📍 University of California, Los Angeles — Los Angeles, California
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
📍 Local Institution - 0011 — Huntsville, Alabama
View Study & Checklist ➔Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
📍 University of Florida — Gainesville, Florida
View Study & Checklist ➔Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
📍 Loma Linda University Cancer Center — Loma Linda, California
View Study & Checklist ➔Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
📍 Masonic Cancer Center at University of Minnesota — Minneapolis, Minnesota
View Study & Checklist ➔Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
📍 Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
View Study & Checklist ➔Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
📍 University of Illinois at Chicago — Chicago, Illinois
View Study & Checklist ➔Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Cladribine Venetoclax in Monocytic AML
📍 Universtiy of Colorado Hospital — Aurora, Colorado
View Study & Checklist ➔Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
📍 Los Angeles General Medical Center — Los Angeles, California
View Study & Checklist ➔Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
View Study & Checklist ➔A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
📍 City of Hope — Duarte, California
View Study & Checklist ➔Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
📍 Boston Children's Hospital — Boston, Massachusetts
View Study & Checklist ➔Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
📍 Lafayette Family Cancer Center-EMMC — Brewer, Maine
View Study & Checklist ➔Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
📍 Stanford University — Palo Alto, California
View Study & Checklist ➔Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia
📍 University of Rochester Medicine — Rochester, New York
View Study & Checklist ➔Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia
📍 Vancouver General Hospital — Vancouver, British Columbia
View Study & Checklist ➔A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
📍 Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
📍 University of Colorado — Aurora, Colorado
View Study & Checklist ➔Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
📍 Illinois CancerCare-Bloomington — Bloomington, Illinois
View Study & Checklist ➔Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
📍 Masonic Cancer Center — Minneapolis, Minnesota
View Study & Checklist ➔Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
📍 Banner University Medical Center - Tucson — Tucson, Arizona
View Study & Checklist ➔Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
📍 Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
View Study & Checklist ➔ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
📍 Washington University — St Louis, Missouri
View Study & Checklist ➔A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
📍 Mayo Clinic Arizona — Phoenix, Arizona
View Study & Checklist ➔Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
📍 Fred Hutchinson Cancer Center/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
📍 UCSF-Fresno — Clovis, California
View Study & Checklist ➔Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
📍 University of Miami — Miami, Florida
View Study & Checklist ➔Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
📍 City of Hope National Medical Center /ID# 279568 — Duarte, California
View Study & Checklist ➔Motixafortide for MRD Sensitization in AML
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔